AMPH vs HALO: fair value comparison
Amphastar Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| AMPH | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $20.22 | $82.27 |
| 12-month range | $18.42–$30.81 | $63.96–$82.27 |
| Sector rank | #15 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | C- | A |
| Momentum grade | A | A |
| Leverage | Moderate | High |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AMPH fair value analysis · HALO fair value analysis